| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net (loss) income | -471 | -7,453 | -1,247 | 2,749 |
| Depreciation | 1,054 | 1,015 | 1,008 | 1,958 |
| Amortization of intangible assets | 267 | 292 | 411 | 815 |
| Intangible asset impairment | NaN | 12,181 | NaN | NaN |
| Amortization of financing fees | 66 | 66 | 66 | 133 |
| Debt modification expense | NaN | 0 | NaN | NaN |
| Stock-based compensation | -1 | 237 | 236 | 462 |
| Deferred income tax expense | 328 | 2,665 | 485 | -609 |
| Accounts receivable | 529 | 2,919 | -1,267 | 2,702 |
| Inventories | 3,311 | 1,218 | 2,229 | -1,102 |
| Prepaid expenses and other assets | 740 | 717 | 2,173 | -4,577 |
| Income taxes receivable and payable | NaN | -170 | NaN | NaN |
| Accounts payable and other liabilities | 6,249 | 2,840 | 3,344 | -400 |
| Net cash provided by operating activities | 2,256 | 1,489 | 198 | 9,303 |
| Proceeds from sale of equipment | NaN | NaN | 4 | NaN |
| Purchase of electrochem | NaN | 0 | NaN | NaN |
| Purchases of property, plant and equipment | 770 | 882 | 995 | 1,995 |
| Net cash used in investing activities | -770 | -886 | -991 | -1,995 |
| Payment of debt issuance costs | NaN | 0 | 0 | 24 |
| Proceeds from exercise of stock options | NaN | 0 | 37 | 61 |
| Borrowings on credit facility | NaN | 0 | NaN | NaN |
| Payments on credit facilities | -2,063 | -687 | -688 | -3,375 |
| Net cash used in financing activities | -2,063 | -687 | -651 | -3,338 |
| Effect of exchange rate changes on cash | 122 | 169 | -237 | 117 |
| Increase (decrease) in cash | -455 | 85 | -1,681 | 4,087 |
| Cash - beginning of year | 9,345 | 9,260 | 6,854 | NaN |
| Cash - end of year | 8,890 | 9,345 | 9,260 | NaN |
ULTRALIFE CORP (ULBI)
ULTRALIFE CORP (ULBI)